Category: Turkiye

  • Zeynep Cakmak Leaves White & Case in Istanbul

    Zeynep Cakmak Leaves White & Case in Istanbul

    White & Case has confirmed that Partner Zeynep Cakmak, the co-Managing Partner of associated Turkish firm Cakmak-Gokce Law Firm, will leave the firm and withdraw from the White & Case partnership on January 31, 2018 to re-join the Cakmak Avukatlik Ortakligi, after which White & Case will provide Turkish law advice in Istanbul through a professional association with a sole proprietorship of Partner Guniz Gokce.

    A White & Case spokesperson commented that, “Zeynep has made a substantial contribution to the service we provide our clients in Turkey, and we wish her every success in her future endeavors. Guniz Gokce has been appointed Istanbul Office Executive Partner, effective February 1, 2018. White & Case is committed to its clients in Turkey, where we have been active for nearly 40 years with an office in Istanbul since 1985.”

    Zeynep joined the local firm in Ankara in 1994, and was elected a partner of White & Case in 2010.

    Cakmak has been associated with White & Case for over 20 years, first (from 1994-2015) with the Cakmak Law Firm, the Turkish firm associated with White & Case in Ankara, and in September 2015 she moved to Istanbul to become Co-Managing Partner of Cakmak-Gokce (as reported by CEE Legal Matters on September 21, 2015). She was elected a partner at White & Case in 2010.

    According to White & Case, the formal name of the new local firm headed by Guniz Gokce is yet to be decided.

  • Turunc Advises Taxim Capital on Acquisition of Majority Stake in Turkish Lingerie Company

    Turunc Advises Taxim Capital on Acquisition of Majority Stake in Turkish Lingerie Company

    Turunc has advised Taxim Capital on its acquisition of 51% of Turkey’s Suwen lingerie and underwear manufacturer and retailer for an undisclosed price.

    Taxim Capital is, according to its website, “a Turkey-focused mid-market private equity firm specializing in control-oriented growth capital investments and shareholder / management buy-outs.” This is the firm’s third investment. Turunc also advised Taxim on its 2016 acquisition of a 40% stake in the Turkish casual dining chain Big Chefs from shareholders Gamze Cizreli and Saruhan Tan (as reported by CEE Legal Matters on September 20, 2016).

    The Turunc team consisted of Kerem Turunc, Nilay Enkur, Didem Bengisu, Gozde Kiran, and Naz Esen, along with intellectual property expert Beste Yildizili and competition law specialist Esin Camlibel.

    The sellers did not retain external counsel.

  • DOJ Makes the Pilot Program Permanent and Announces  FCPA Corporate Enforcement Policy

    DOJ Makes the Pilot Program Permanent and Announces FCPA Corporate Enforcement Policy

    The US Department of Justice (“DOJ”) had announced a pilot program1 (“Pilot Program”) on April 5, 2016, which created new mitigation opportunities for companies that (i) voluntarily self-disclosed, (ii) cooperated fully, and (iii) took timely and appropriate remedial actions in FCPA matters that fell within the Fraud Section’s mandate.

    The Pilot Program was to remain in effect for 1 year, starting from the day of its announcement. On March 10, 2017, the Acting Assistant Attorney General, Kenneth A. Blanco, announced in a speech that the Pilot Program would continue in full force until the DOJ reached a final decision on whether to extend it, and what revisions, if any, should be made to it.2 The evaluation period of the Pilot Program ended on November 29, 2017, when Deputy Attorney General Rod Rosenstein announced the new FCPA Enforcement Policy (“Policy”), which effectively makes the Pilot Program permanent with some revisions. According to Deputy Attorney General Rosenstein, the FCPA Unit received 30 voluntary disclosures during the time period that the Pilot Program was in force, as opposed to 18 voluntary disclosures that were received during the previous 18-month period. The Policy has been incorporated into the United States Attorneys’ Manual in order to “be readily understood and easily applied by busy prosecutors” as opposed to being promulgated in memorandum format.3

    Deputy Attorney General Rosenstein highlighted a few key aspects of the new Policy during his speech on November 29. Accordingly, there will be a presumption that, if a company duly engages in voluntary self-disclosure, full cooperation, and timely and appropriate remediation, then that company will be granted a declination decision. However, this presumption may not be applicable in certain cases, depending on the seriousness of the offense and whether the company is a recidivist (i.e., whether it has previously engaged in such misconduct.) Furthermore, in case a company satisfies all of the requirements of the Policy, but aggravating circumstances exist that necessitate an enforcement action, then the DOJ will recommend a 50% fine reduction off of the low end of the fine range that is set forth in the Sentencing Guidelines. The new Policy also helps to concretize and shed light on the elements of an effective compliance program, by putting forth specific conditions, such as the compliance department being provided with sufficient resources and the compliance personnel having access to the management team and the board of directors of their companies. Deputy Attorney General Rosenstein also stated that the Policy is aimed at clarifying the DOJ’s decision-making processes. He also declared that the Policy concerns the internal operating policies of companies and noted that it did not create any private rights. 

    I. What Advantages Does the New Policy Bring?

    The advantages brought about by the Policy are similar to those provided under the Pilot Program; however, they are stated in clearer and more concrete language. Under the Policy, the DOJ will act under the presumption that it will give a declination decision for those who (i) voluntarily self-disclose, (ii) cooperate fully, and (iii) take timely and appropriate remedial actions. This section of the Policy differs significantly from the Pilot Program, where there was no presumption of a declination decision but only a promise. As opposed to the a priori nature of a presumption, a promise is a weaker potential decision. 

    However, if a particular case requires a criminal resolution, then the DOJ will “(i) accord, or recommend to a sentencing court, a 50% reduction off of the low end of the U.S. Sentencing Guidelines (“USSG”) fine range, except in the case of a criminal recidivist; and (ii) generally will not require appointment of a monitor if a company has, at the time of resolution, implemented an effective compliance program.”4

    Furthermore, companies have to make all disgorgement, forfeiture and/or restitution payments resulting from the misconduct in order to qualify for the Policy, as was the case with the Pilot Program.

    Similar to the Pilot Program, the Policy continues to provide advantages for companies that fail to voluntarily self-disclose, but nevertheless (i) cooperate fully and (ii) remediate in a timely and appropriate fashion. These companies will be awarded up to a 25% reduction off of the low end of the fine range that is provided by the US Sentencing Guidelines (“USSG”). 

    II. How Can Companies Become Eligible for the Policy?

    In order to benefit fully from the Policy, companies have to (i) voluntarily self-disclose, (ii) cooperate fully, and (iii) take timely and appropriate remedial actions with regard to FCPA matters.

    1. Voluntary Self-Disclosure

    The DOJ will require the fulfillment of the following criteria for a company to receive credit for voluntary self-disclosure of wrongdoing: “(i) The voluntary disclosure qualifies under USSG Section 8C2.5(g)(1) as occurring “prior to an imminent threat of disclosure or government investigation”; (ii) the company discloses the conduct to the DOJ “within a reasonably prompt time after becoming aware of the offense,” with the burden being on the company to demonstrate timeliness and (iii) the company discloses all relevant facts known to it, including all relevant facts about all individuals involved in the violation of law.”5

    2. Full Cooperation in FCPA Matters

    The following are the criteria that must be met for a company to be considered “fully cooperative” under the Policy, similar to the Pilot Program: 

    “(i) Disclosure on a timely basis of all facts relevant to the wrongdoing at issue, including: all relevant facts gathered during a company’s independent investigation; attribution of facts to specific sources where such sources does not violate the attorney-client privilege, rather than a general narrative of the facts; timely updates on a company’s internal investigation, including but not limited to rolling disclosures of information; all facts related to involvement in the criminal activity by the company’s officers, employees, or agents; and all facts known or that become known to the company regarding potential criminal conduct by all third-party companies (including their officers, employees, or agents);

    (ii) Proactive cooperation, rather than reactive; that is, the company must timely disclose facts that are relevant to the investigation, even when not specifically asked to do so, and, where the company is or should be aware of opportunities for the Department to obtain relevant evidence not in the company’s possession and not otherwise known to the Department, it must identify those opportunities to the Department;

    (iii) Timely preservation, collection, and disclosure of relevant documents and information relating to their provenance, including (a) disclosure of overseas documents, the locations in which such documents were found, and who found the documents, (b) facilitation of third-party production of documents, and (c) where requested and appropriate, provision of translations of relevant documents in foreign languages;

    (iv) Where requested, de-confliction of witness interviews and other investigative steps that a company intends to take as part of its internal investigation with steps that the Department intends to take as part of its investigation; and

    (v) Where requested, making available for interviews by the Department those company officers and employees who possess relevant information; this includes, where appropriate and possible, officers, employees, and agents located overseas as well as former officers and employees (subject to the individuals’ Fifth Amendment rights), and, where possible, the facilitation of third-party production of witnesses.”6

    According to the Policy, if a company claims that it cannot disclose overseas documents due to data privacy rules and regulations, blocking statutes or other reasons related to foreign law, the burden falls upon the company to establish and provide evidence for such a prohibition. 

    3. Timely and Appropriate Remediation in FCPA Matters

    The following are the criteria that must be fulfilled in order for a company to receive full credit for timely and appropriate remediation, similar to the Pilot Program:

    “(i) Demonstration of thorough analysis of causes of underlying conduct (i.e., a root cause analysis) and, where appropriate, remediation to address the root causes;

    (ii) Implementation of an effective compliance and ethics program, the criteria for which will be periodically updated and which may vary based on the size and resources of the organization, but may include:

    (a) The company’s culture of compliance, including awareness among employees that any criminal conduct, including the conduct underlying the investigation, will not be tolerated;

    (b) The resources the company has dedicated to compliance;

    (c) The quality and experience of the personnel involved in compliance, such that they can understand and identify the transactions and activities that pose a potential risk;

    (d) The authority and independence of the compliance function and the availability of compliance expertise to the board;

    (e) The effectiveness of the company’s risk assessment and the manner in which the company’s compliance program has been tailored based on that risk assessment;

    (f) The compensation and promotion of the personnel involved in compliance, in view of their role, responsibilities, performance, and other appropriate factors;

    (g) The auditing of the compliance program to assure its effectiveness; and

    (h) The reporting structure of any compliance personnel employed or contracted by the company.

    (iii) Appropriate discipline of employees, including those identified by the company as responsible for the misconduct, either through direct participation or failure in oversight, as well as those with supervisory authority over the area in which the criminal conduct occurred;

    (iv) Appropriate retention of business records, and prohibiting the improper destruction or deletion of business records, including prohibiting employees from using software that generates but does not appropriately retain business records or communications; and

    (v) Any additional steps that demonstrate recognition of the seriousness of the company’s misconduct, acceptance of responsibility for it, and the implementation of measures to reduce the risk of repetition of such misconduct, including measures to identify future risks.”7

    In general, we observe that the Pilot Program and the new Policy do not differ with respect to their substances or contents, but in their promises. As can be understood from the speech given by Deputy Attorney General Rosenstein on November 29, 2017, the Policy, which will henceforth be in permanent effect, aims to provide more clarity as to how the DOJ will act with respect to companies that have engaged in misconduct, but have also duly satisfied three essential criteria, namely: (i) voluntary self-disclosure, (ii) full cooperation, and (iii) timely and appropriate remediation. 

    (First published in Mondaq on December 7, 2017) 

    1. For more information regarding the Pilot Program, please see ELIG’s previous article: DOJ Launches FCPA Pilot Program For Voluntary Self Disclosure, What does it Offer? 
    2. See https://www.justice.gov/opa/speech/acting-assistant-attorney-general-kenneth-blanco-speaks-american-bar-association-national 
    3. See https://www.justice.gov/opa/speech/deputy-attorney-general-rosenstein-delivers-remarks-34th-international-conference-foreign 
    4. United States Attorneys’ Manual, 9-47.120. 
    5. Ibid.
    6. Ibid.
    7. Ibid.

    By Gonenç Gurkaynak, Managing Partner, C. Olgu Kama, Partner, and Burcu Ergun, Associate, ELIG, Attorneys-at-Law

  • Denel Kirali Joins ASC as Partner

    Denel Kirali Joins ASC as Partner

    Turkish lawyer Denel Balci Kirali has joined the ASC Law Office as a Partner.

    After obtaining her law degree from the Dokuz Eylul University in Izmir, Kirali worked in private practice for several years before joining the legal department of Garanti Bank in 2003, then moving to Deutsche Bank in 2007. In 2012 she accepted a founding role as Chief Legal Counsel and Corporate Secretary of Odeabank A.S. (in the Bank Audi Group), where, she reports, she “executed all the necessary legal and regulatory work during the start-up phase of business, including the establishment of the bank and the obtaining of an operating license.” She says she “founded the legal department (including both advisory and litigation sections) and prepared all necessary legal documentation, agreements and forms for the bank.” 

    From 2015 until her move to ASC she provided advice to the Volkswagen Dogus Finansman Group Companies.

  • Baker McKenzie Advises on Yapi Kredi Million Dual Currency Syndicated Term Loan Facilities

    Baker McKenzie Advises on Yapi Kredi Million Dual Currency Syndicated Term Loan Facilities

    The Esin Attorney Partnership and Baker McKenzie have advised a syndicate of 37 international banks, including Bank of America Merrill Lynch International Limited as Sole Bookrunner and Documentation Agent, on EUR 800 million and USD 411 million dual currency term loan facilities provided to Yapi ve Kredi Bankasi A.S. The deal was signed on October 9, 2017. 

    According to the Esin Attorney Partnership, the transaction involves “two 367-day facilities and two 2 year + 1 business day facilities, denominated in US dollars and euros, paying all-in spread of 135 bps, 125 bps, 220 bps and 210 bps respectively.”     

    In addition to its role as Sole Bookrunner and Documentation Agent, Bank of America Merrill Lynch was Joint Coordinators with ICBC Yaitirim, and UniCredit Bank AG acted as Facility Agent for the facilities, which refinances Yapi Kredi’s previous syndicated loan facilities, which were signed on October 4, 2016.   

    The transaction was led by Paris-based Baker McKenzie Partner Michael Foundethakis and Esin Attorney Partnership’s Head of Banking & Finance, Partner Muhsin Keskin. The team also included Senior Associates Luka Lightfoot (London) and Thomas Lefebvre (Paris) and Associates Max Jones (London), Berk Cin (Istanbul), and Erdi Yildirim (Istanbul).

    The Esin Attorney Partnership and Baker McKenzie also advised the lenders on a separate USD 155 million term loan facility to Yapi Kredi, also signed on October 9 (as reported by CEE Legal Matters on October 24, 2017).

  • Disputes on Health-Related Commercial Advertisements under Consumer Law

    The Law on Protection of Consumers No. 6502 (the “Law”) is published in the Official Gazette on November 28, 2013 and entered into force on May 28, 2014. Article 1 of the Law specifies the purpose of the Law as “to take measures that protect the health, safety and the economic interests of the consumer … in order to inform and educate the consumers in accordance with public interest”. Regulation and supervision of advertisements are considered as necessary tools to protect consumers. Therefore the Law includes detailed provisions on advertisements, which are supported by the secondary legislation, i.e. the Regulation on Commercial Advertisement and Unfair Commercial Practices (the “Regulation”). 

    Under Turkish law certain sectors, such as health sector, are subject to additional restrictions on advertising due to their unique nature and purpose. As a general rule, health-related commercial advertisements are prohibited under Turkish law through various pieces of legislation. Administrative sanctions are set to be imposed by the Advertisement Board on the advertisers, advertising agencies and establishments broadcasting these advertisements in cases where the health-related commercial advertisements are considered to be contrary these restrictions. Since the Advertisement Board’s decisions are deemed as administrative actions under Turkish administrative law, these decisions are subject to judicial review before administrative courts. The Council of State rendered many decisions in cases where sanctions on health-related commercial advertisements are challenged and requested to be annulled, and these decisions provide further guidance on how the restrictions must be interpreted and viewed, specifically what makes a health-related commercial advertisement illegal under Turkish law. 

    Commercial Advertisement under Turkish Law

    Article 61 of the Law defines “commercial advertisement” as “announcements that are marketing communications made through written, visual, audio and similar methods in any medium by the advertisers, in order to provide sale or lease of a good or service, inform or convince target audience in connection with a trade, work, craft or profession”. Scholars argue that there are different definitive elements in commercial advertisements, such as existence of promotion, commercial aim, intention to promote, purpose of increasing popularity of a product or service, use of a medium, and addressing the public, i.e. more than one individual. 

    Commercial advertisements are subject to regulations as they are considered to be inextricably linked to protection of consumers. Article 61 of the Law provides the main rules regulating commercial advertisements, which are elaborated and supported by the provisions of the Regulation. Article 77(12) of the Law specifies the administrative sanctions that may be imposed on advertisers, advertising agencies and establishments broadcasting the advertisements by the Advertisement Board in case of non-compliance to the regulations. 

    Prohibited and Restricted Advertisements in the Context of Health Sector

    Article 61(2) of the Law provides that commercial advertisements must be in conformity with the principles adopted by the Advertisement Board, public morality, public order and personal rights; they also must be honest and true. Commercial advertisements that deceive or mislead the consumer, or abuse the consumer’s lack of experience or knowledge, threatening the life of the consumer and safety of consumer’s property, encouraging the acts of violence or inciting to commit crime, endangering public health, abusing the sick, elderly, children or disabled people are prohibited by Article 61(3) of the Law. In addition to these general rules, the Regulation provides more specific rules that need to be observed.

    Article 26(1) of the Regulation titled “goods and services subject to special rules on advertisement” provides that “advertisements of goods and services that which are subject to special rules on advertisement, such as … health services …, must be in conformity with all the other rules on advertisement and promotion provided in the relevant legislation.” Therefore, while examining the health-related commercial advertisements, specific legislations must be taken into consideration.

    First of all, medical institutions and medical staff are not allowed to be involved in health-related commercial advertisements in order to prevent commercialization of human health and to observe public interest (common good) during the provision of healthcare services. Article 24 of the Law on Execution of Medicine and Medical Sciences No. 1219 provides an exception to the prohibition on medical staff being involved in commercial advertisement. This article stipulates that medical doctors are allowed to make announcements regarding the location of their clinic, working hours and their specialization; but they still cannot make advertisements regarding any other issue.  

    Article 60(2) of the Regulation on Private Hospitals allows private hospitals to make promotions and inform public only with the purpose of preservation and enhancement of health. That being said, Article 60(1) prohibits actions and promotions made by private hospitals that are considered to be contrary to medical deontology and ethical rules, which could deceive or mislead individuals or aim to increase demand of individuals or constitute unfair competition vis a vis other private hospitals. In the same vein, Article 29(1) of the Regulation on Private Medical Centers for Ambulatory Diagnosis and Treatment explicitly provides that “medical institutions cannot be involved in advertisement”. The Ministry of Health’s Circular on Private Medical Institutions’ Informatory and Promotional Activities No. 2013/15 provides that “Explicit and implicit advertisements going beyond being informative and promotional shall be prohibited.”

    Supervision of Commercial Advertisements and Sanctions in the Context of Health Sector

    The Advertisement Board has the authority to supervise commercial advertisements and to impose sanctions of suspension, correction, monetary fine, or precautionary suspension up to three (3) months in case of non-compliance pursuant to Article 63 of the Law. There are numerous decisions rendered by the Advertisement Board wherein the Board imposed sanctions on the commercial advertisements made by medical institutions and/or medical staff that (i) exceed the informatory purposes, (ii) render the activities of the medical institutions and/or medical staff as commercial activities, (iii) aim to create demand, and (iv) constitute unfair competition vis a vis other medical institutions and/or medical staff. These are the general restrictions that a health-related advertisement is bound by. 

    Precedents concerning Advertisements in Health Sector 

    Under Turkish law, the Advertisement Board’s decisions are deemed as administrative actions and it is possible to initiate an annulment lawsuit against the Advertisement Board’s decisions before the administrative courts. Various decisions of the Administrative Board related to health-related commercial advertisements were challenged through annulment lawsuits and the Council of State, the highest administrative court in Turkey, rendered many decisions in these cases, which provide further guidance on the restrictive rules on health-related commercial advertisements. Below are just a few of these decisions that could be an example to what makes a health-related advertisement being contrary to the allowed framework of such advertisements. 

    15th Administrative Chamber of the Council of State, with its decision dated December 15, 2015 and numbered 2015/8726 E., 2015/8764 K., confirmed an administrative court’s decision wherein it was concluded that mentioning the contact details of the medical doctors working at a hospital in an advertisement published in a newspaper makes the hospital’s activities seem like commercial activities. 

    15th Administrative Chamber of the Council of State, in its decision dated October 1, 2015 and numbered 2015/4050 E., 2015/5574 K., stated that advertisement published in a magazine containing statements such as “… the new technology is available at [the name of the hospital]” and the “before and after” photos of the patients aims to create demand for the relevant hospital, which renders the relevant hospital’s activities as commercial activities and constitutes unfair competition vis a vis other medical institutions. 

    15th Administrative Chamber of the Council of State in its decision dated September 18, 2015 and numbered 2015/6917 E., 2015/5437 K. ruled that provision of detailed description of the treatments provided at a dental clinic by mentioning that all those treatments are successfully applied by the dentists working at that clinic and presentation of photos of the clinic was again considered as aiming to create demand, rendering the clinic’s activities as commercial activities, and constituting unfair competition. 

    15th Administrative Chamber of the Council of State in its decision dated December 19, 2011 and numbered 2011/11279 E., 2011/5725 K. ruled that an advertisement that is published in a newspaper regarding a discount in vitro fertilization procedure limited with 500 families and gives contact details of the relevant hospital is contrary to law, as the advertisement aims to increase the demand for the relevant hospital and commercialize its activities. 

    15th Administrative Chamber of the Council of State in its decision dated November 21, 2011 and numbered 2011/1472 E., 2011/4167 K. ruled that the articles published in a magazine, which states that an hospital receives patients transferred from another hospital abroad and gives out contact details and opinions of the medical doctors working at that hospital abroad, is a commercial advertisement aiming to direct more patients to the hospital and medical doctors receiving transferred patients.

    15th Administrative Chamber of the Council of State in its decisions dated December 21, 2011 and numbered 2011/12449 E., 2011/5843 K. and dated November 28, 2011 and numbered 2011/12437 E., 2011/4435 K. ruled that an advertisement on prostate treatment titled “Stay always young, just like me”, which also has the internet address of the relevant hospital, creates commercial appearance for the relevant hospital and aims to increase the demand for the relevant hospital.

    9th Administrative Chamber of Ankara Regional Administrative Court in its very recent decision dated February 9, 2017 and numbered 2017/55 E., 2017/60 K. ruled that an advertisement suggesting that a public dental clinic to be a better clinic due to its high quality treatment facilities compared to private dental clinics directly incentivizes the patients to choose that public dental clinic, which is contrary to law in terms of restrictions in health-related advertisements. 

    In light of all these decisions, it is possible to say that health-related advertisements are considered to be illegal if these advertisements promote the health institution to attract patients, praise a medical procedure by implying that the procedure brings a positive effect despite that specific effect being irrelevant to that procedure, create attraction for the health institution by suggesting the institution is highly preferred, announce discounts on a medical procedure to steer patients into choosing the institution making that discount, suggest all the medical procedures are completed successfully in order to create a sense of confidence and thus patient demand. Surely these circumstances are mere examples of what constitutes an illegal health-related advertisement and any circumstance that exceeds the allowed framework of restrictive rules on health-related commercial advertisements would make the advertisement illegal. 

    Conclusion

    The Law regulates commercial advertisement through the Regulation. Since the health sector is subject to special restrictions on advertisement due to special place in terms of public benefit, specific pieces of legislation become applicable when a health-related commercial advertisement is in question. As a general rule, health-related commercial advertisements are prohibited under Turkish law except for those aiming to inform the individuals. The Advertisement Board rendered many decisions in cases where health-related commercial advertisements are found (i) exceeding the informatory purposes, (ii) rendering the activities of the medical institutions and/or medical staff as commercial activities, (iii) aiming to create demand, and (iv) constituting unfair competition vis a vis other medical institutions and/or medical staff. The local administrative courts and the Council of State have adopted the same criteria while examining the legality of a health-related commercial advertisement by considering unique dynamics and specifics of each case. 

    By Gonenç Gurkaynak, Managing Partner, Tolga Uluay, Associate, and A. Bahadır Erkan, Associate, Elig, Attorneys-at-Law

    (First published in Mondaq on December 5, 2017)

  • Applicability of Foreign Anti-Bribery and Corruption Legislation and Statutory Provisions in Turkey

    Foreign investors willing to invest in Turkey and Turkish companies listed on foreign stock exchanges or which have a business relationship with foreign companies are under the obligation to comply with high-level international compliance requirements. As a result, these investors and Turkish companies are required to implement compliance programs which assist them and their employees to conduct transactions and actions in conformity with ethical principles, legislation, and regulatory provisions. 

    The US Foreign Corrupt Practices Act (FCPA) and UK Bribery Act are the main compliance regulations with cross-border effects. The FCPA was made effective by the US Department of Justice and the Securities and Exchange Commission (SEC) on December 19, 1977. The UK Bribery Act entered into force in July 2011. Turkish companies which have business relationships with US and UK companies are obliged to comply with these acts. 

    In addition, Turkey has ratified several international anti-corruption conventions, such as the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, the United Nations Convention against Transnational Organized Crime, the United Nations Convention against Corruption, and several European Conventions on Criminal and Civil Law.

    Current Status in Turkey

    Turkish Criminal Code No. 5237 is the primary regulation dealing with corruption in Turkey. The relevant provision criminalizes bribery, misuse of trust, fraud, laundering asset values arising from criminal activities, rigging the performance of an obligation, exposing commercial secrets, and forgery. Article 252 of the Turkish Criminal Code defines “bribe” as a benefit illegally secured by a public officer in negotiation with a person to perform or not to perform a task beyond his or her responsibility. Accordingly, any public officers who take bribes will be punished, along with the person offering the bribe. In addition, bribery is committed where a benefit is provided, offered, or promised directly or through intermediaries; or where the relevant individuals request or accept such a benefit directly or through intermediaries.

    In addition, the Turkish Civil Servants Law strictly prohibits civil servants from requesting and accepting gifts. In accordance with this Law, the Public Officials Ethics Board (the “Ethics Board”) is authorized to determine the scope of this prohibition.

    The Ethics Board was established pursuant to the Ethics Rules Law, which was created to adopt rules and monitor public officials’ implementation of principles related to transparency, impartiality, honesty, accountability, and obligation to observe the public interest. 

    Compliance Challenges of the Turkish Companies

    Today, although Turkish companies are more willing than ever to establish business relationships with overseas countries which have anti-bribery and corruption legislation; they face several significant obstacles on their way to compliance. 

    The first of these obstacles is the international corruption perception of Turkey; which, according to the Corruption Perception Index (CPI) of Transparency International, has declined over the last four years from 50 in 2013, to 45, 42, and ultimately 41 in 2016.

    As the index is one of the primary indicators foreign investors consider prior to investing in a country, the decline means that Turkish companies have a greater challenge to overcome in attempting to demonstrate their willingness for international cooperation.

    Unfortunately, applicable local legislation is not specific and clear in terms of what companies need to do in order to comply with anti-bribery and anti-corruption prohibitions. Therefore, Turkish companies would definitely need a solid compliance guide. 

    The second obstacle is that even those Turkish companies which do have a strong anti-bribery and anti-corruption company culture often transmit it verbally instead of in written policies, procedures, or codes of conduct. 

    Anti-corruption and anti-bribery trainings that would communicate important policies and procedures and third party due diligences are essential mechanisms that Turkish companies need to implement. In addition, although a significant compliance program component is a whistleblowing mechanism that employees can use to report violations anonymously, reporting a serious issue about a co-worker still comes up against a cultural barrier in Turkey, although this barrier could perhaps be eliminated with the help of effective trainings. 

    One last element of an effective compliance program that Turkish companies need to implement is a corruption and bribery risk analysis of processes to address the specific risks they face. 

    Conclusion

    Turkish companies face certain difficulties in achieving compliance with anti-bribery and anti-corruption legislation. They also have two very important factors working in their favor, however: their economic potential and their strong desire for business partnerships with overseas companies. These will lead their efforts on compliance.

    By Semih Metin and Cigdem Gurer, Partners, Nazali Tax & Legal

    This Article was originally published in Issue 4.9 of the CEE Legal Matters Magazine. If you would like to receive a hard copy of the magazine, you can subscribe here.

  • Kolcuoglu Demirkan Kocakli and Verdi Law Firm Advise on Actera Partners II Acquisition of Majority Stake in Gratis

    Kolcuoglu Demirkan Kocakli and Verdi Law Firm Advise on Actera Partners II Acquisition of Majority Stake in Gratis

    Kolcuoglu Demirkan Kocakli, working in cooperation with Fox Horan & Camerini, has advised Demir Sabanci on the indirect sale of the majority shares of Gratis Ic ve Dis Ticaret Anonim Sirketi to Actera Partners II L.P. Kirkland & Ellis represented Actera Partners II, with Verdi Attorney Partnership advising on Turkish law matters.

    KDK reports that its team “assisted the client in the due diligence process, negotiated the transaction documents, and handled the signing process.” The parties signed the transaction documents on November 28, 2017.

    The KDK team was led by Partner Umut Kolcuoglu and included Associates Bihter Bozbay and Gizem Zeynep Bolukbasi.

    The Verdi team was led by Partner Can Verdi and included Associates Ayse Atakan, Cem Avaroglu, and Mevce Kuntay.

  • Moral and Kolcuoglu Demirkan Kocakli Advise on Turkven Private Equity Acquisition of Majority Stake in Vansan

    Moral and Kolcuoglu Demirkan Kocakli Advise on Turkven Private Equity Acquisition of Majority Stake in Vansan

    Moral has represented the shareholders of Vansan Makina Sanayi ve Ticaret A.S.on the acquisition of a majority stake in the company by Turkven Private Equity. Kolcuoglu Demirkan Kocakli advised the buyers on the deal.

    According to Moral, “Vansan is the leading centrifugal water extraction pump and motor manufacturer with two factories of 17,000 square meters closed production area, an extensive dealer network, and 500 employees as of 2017. The company serves worldwide agribusinesses, power plants, industrial companies and municipalities.”

    The Moral team was led by Partners Resat Moral and Serkan Pamukkale and Senior Associate Karaca Kacar.

    The KDK team was led by Partner Umut Kolcuoglu and included Associates Bihter Bozbay and Duygu Dursun.

  • Turkey’s Nazali Tax & Legal to Formally Adopt Andersen Name

    Turkey’s Nazali Tax & Legal to Formally Adopt Andersen Name

    The Nazali Tax & Legal firm in Istanbul has announced that it will officially adopt the Andersen Global name in January 2018 and will operate henceforth as a full-fledged member firm of Andersen Global.

    Nazali, which was founded in 2015 by Managing Partner Ersin Nazali and which has locations in Istanbul, Ankara, Izmir, and Bursa, formalized its collaboration agreement with Andersen Global this past summer (as reported by CEE Legal Matters on July 17, 2017). In its announcement of the adoption of the Andersen name, Nazali and fellow Managing Partner Cagdas Guren are quoted as declaring that: “The adoption of the Andersen name demonstrates the next step to further extending our boundaries and integrating our team globally. We are excited to continue strengthening our practice and capabilities, and together we will strive to find the best solutions for our clients. Incorporating additional offerings internationally and extending our support will help us build on our foundation and further provide seamless coverage in key markets.”

    Global Chairman and Andersen Tax LLC CEO Mark Vorsatz added, “the team in Turkey is dedicated, passionate, and have shown outstanding commitment to client service. They are an excellent fit for our firm, our clients, and our core principles.”